| Therapeutic area | Candidate | Target | Validation | Preclinical | Phase I | Phase II |
|---|---|---|---|---|---|---|
| Oncology | IPH 2101 | KIR2DL1,2,3 | Multiple Myeloma / MMy | |||
| Acute Myeloïd leukemia / AML | ||||||
| IPH 4101 | KIR3DL2 | CTCL | ||||
| Inflammation | IPH 2201 (NN8765) | undiclosed | Inflammation autoimmunity | |||
| IPH 24 | undisclosed | Inflammation autoimmunity | ||||
| Oncology infections | IPH 1101 | γδ TCR | Follicular Non-Hodgkin’s Lymphoma / fNHL | |||
| Type C Hepatitis / HCV (closed) | ||||||
| IPH 1201 | γδ TCR | Infectious diseases | ||||